Anticancer potential of 2,2'-bipyridine hydroxamic acid derivatives in head and neck cancer therapy

Area of Science:

• Oncology
• Medicinal Chemistry
• Cancer Biology

Background:

• Head and neck cancer (HNC) treatment faces challenges with current chemotherapies due to toxicity and resistance.
• Hydroxyurea, an anticancer agent, has limitations including short half-life and toxicity.
• Developing novel derivatives with improved properties is crucial for effective HNC therapy.

Purpose of the Study:

• To design and synthesize novel 2,2'-bipyridine hydroxamic acid derivatives, including a hydroxyurea analogue, for HNC treatment.
• To evaluate the chemotherapeutic efficacy and safety of these new compounds.
• To investigate the mechanism of action of promising candidates.

Main Methods:

• Synthesis of two novel 2,2'-bipyridine hydroxamic acid derivatives.
• Assessment of selective cytotoxicity against Cal27 HNC cells.
• Mechanistic studies including cell migration assays, reactive oxygen species (ROS) detection, and apoptosis assays.
• Histone deacetylase (HDAC) inhibition assays, molecular docking, and molecular dynamics simulations.

Main Results:

• Compound 1A, a hydroxyurea analogue, exhibited selective cytotoxicity against Cal27 cells (IC50 = 19.36 μM).
• Compound 1A demonstrated inhibition of cancer cell migration and induced ROS-mediated apoptosis.
• Compound 1A showed moderate HDAC inhibition, with stable binding to HDAC 2 isoform confirmed by simulations.

Conclusions:

• Compound 1A is a promising lead candidate for head and neck cancer therapy.
• The compound integrates epigenetic modulation (HDAC inhibition) with direct cytotoxic effects.
• Further development of compound 1A could lead to improved HNC chemotherapeutic strategies.